← Leaderboards
Ali Azhdarinia
University Of Texas Hlth Sci Ctr Houston
$2,798,599
Attributed
$3,686,255
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,686,255 · 3
By mechanism
R01$3,686,255 · 3
Top collaborators
- Naruhiko Ikoma3 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Agnes Schonbrunn$3,790,067
- Naruhiko Ikoma$887,656
- Jeffrey A Frost$5,373,835
- Eva M Sevick-Muraca$18,367,261
- Kevin Patric Lally$682,156
Others in their field
Top investigators on “Multimodality”
- Ed Lein · Allen Institute$62,473,096
- Gary Mays · Axle Informatics, Llc$59,047,077
- Mitchell D Schnall · University Of Pennsylvania$58,725,500
- Prasant Mohapatra · University Of California At Davis$54,247,459
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$50,366,173
Research focus
MultimodalityAnalogTumorDetectionChelating AgentsImagePropertyTissuesPerformanceLabelCellsRadiotracerPharmacologyPlayPenetrationImaging ModalityOperative Surgical ProceduresPostoperative PeriodExcisionDesignFluorescenceDyesCaringContrast Media
Grant awards (8)
Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate Cancer$571,271
R01 · FY2025 · CA · contact PI
Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors$485,072
R01 · FY2025 · CA · contact PI
Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors$628,150
R01 · FY2023 · CA · contact PI
Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors$662,090
R01 · FY2022 · CA · contact PI
Development of hybrid somatostatin analogs for surgical guidance$308,348
R01 · FY2017 · EB · contact PI
Development of hybrid somatostatin analogs for surgical guidance$344,221
R01 · FY2016 · EB · contact PI
Development of hybrid somatostatin analogs for surgical guidance$346,944
R01 · FY2015 · EB · contact PI
Development of hybrid somatostatin analogs for surgical guidance$340,159
R01 · FY2014 · EB · contact PI